KR20220078604A - 헤테로시클리덴아세트아미드 유도체 함유 의약 - Google Patents

헤테로시클리덴아세트아미드 유도체 함유 의약 Download PDF

Info

Publication number
KR20220078604A
KR20220078604A KR1020227012080A KR20227012080A KR20220078604A KR 20220078604 A KR20220078604 A KR 20220078604A KR 1020227012080 A KR1020227012080 A KR 1020227012080A KR 20227012080 A KR20227012080 A KR 20227012080A KR 20220078604 A KR20220078604 A KR 20220078604A
Authority
KR
South Korea
Prior art keywords
eye
dry eye
item
composition
ylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012080A
Other languages
English (en)
Korean (ko)
Inventor
다케시 다루이
신야 고바야시
Original Assignee
센주 세이야꾸 가부시키가이샤
모찌다 세이야쿠 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센주 세이야꾸 가부시키가이샤, 모찌다 세이야쿠 가부시끼가이샤 filed Critical 센주 세이야꾸 가부시키가이샤
Publication of KR20220078604A publication Critical patent/KR20220078604A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020227012080A 2019-10-04 2020-10-02 헤테로시클리덴아세트아미드 유도체 함유 의약 Pending KR20220078604A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019184053 2019-10-04
JPJP-P-2019-184053 2019-10-04
PCT/JP2020/037548 WO2021066144A1 (ja) 2019-10-04 2020-10-02 ヘテロシクリデンアセトアミド誘導体含有医薬

Publications (1)

Publication Number Publication Date
KR20220078604A true KR20220078604A (ko) 2022-06-10

Family

ID=75338162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012080A Pending KR20220078604A (ko) 2019-10-04 2020-10-02 헤테로시클리덴아세트아미드 유도체 함유 의약

Country Status (17)

Country Link
US (1) US20220370404A1 (enExample)
EP (2) EP4043014B1 (enExample)
JP (3) JP7025094B2 (enExample)
KR (1) KR20220078604A (enExample)
CN (1) CN114585357A (enExample)
AU (1) AU2020361093A1 (enExample)
BR (1) BR112022005992A2 (enExample)
CA (1) CA3156484A1 (enExample)
DK (1) DK4043014T3 (enExample)
ES (1) ES3031607T3 (enExample)
HU (1) HUE072085T2 (enExample)
MX (2) MX2022004027A (enExample)
MY (1) MY207759A (enExample)
PH (1) PH12022550805A1 (enExample)
PL (1) PL4043014T3 (enExample)
PT (1) PT4043014T (enExample)
WO (1) WO2021066144A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4043014T3 (da) * 2019-10-04 2025-06-23 Senju Pharma Co Farmaceutisk sammensætning indeholdende heterocyklidenacetamid-derivat til brug til behandling af tørre øjne
JP7175431B1 (ja) * 2021-03-30 2022-11-18 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
KR20250065723A (ko) 2022-09-29 2025-05-13 센주 세이야꾸 가부시키가이샤 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액
AU2023352013A1 (en) 2022-09-29 2025-04-03 Mochida Pharmaceutical Co., Ltd. Combination preparation containing heterocyclidene acetamide derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5621566A (en) 1979-08-01 1981-02-28 Alpha- Shokuhin Kk Preparation of bifun from homegrown rice and apparatus used for it
CA2616079C (en) 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
ZA200800959B (en) * 2005-07-22 2009-10-28 Mochida Pharmaceutical Company Novel heterocyclidene acetamide derivative
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
WO2012045729A1 (en) * 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP6230743B1 (ja) * 2017-05-31 2017-11-15 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の結晶
JP7373909B2 (ja) 2018-04-06 2023-11-06 株式会社シマノ 変速制御装置および変速システム
DK4043014T3 (da) * 2019-10-04 2025-06-23 Senju Pharma Co Farmaceutisk sammensætning indeholdende heterocyklidenacetamid-derivat til brug til behandling af tørre øjne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
파마시아 Vol.50 No.3 2014:201 내지 206

Also Published As

Publication number Publication date
DK4043014T3 (da) 2025-06-23
EP4545095A3 (en) 2025-07-02
WO2021066144A1 (ja) 2021-04-08
MX2025005474A (es) 2025-06-02
CA3156484A1 (en) 2021-04-08
JP7025094B2 (ja) 2022-02-24
US20250134854A1 (en) 2025-05-01
CN114585357A (zh) 2022-06-03
EP4545095A2 (en) 2025-04-30
MY207759A (en) 2025-03-17
US20220370404A1 (en) 2022-11-24
ES3031607T3 (en) 2025-07-09
HUE072085T2 (hu) 2025-10-28
JP7248836B2 (ja) 2023-03-29
JP2022065024A (ja) 2022-04-26
AU2020361093A1 (en) 2022-05-19
JP2023011735A (ja) 2023-01-24
MX2022004027A (es) 2022-07-19
EP4043014A4 (en) 2023-10-11
EP4043014B1 (en) 2025-03-19
PL4043014T3 (pl) 2025-08-11
PT4043014T (pt) 2025-06-09
PH12022550805A1 (en) 2023-10-02
BR112022005992A2 (pt) 2022-06-21
JPWO2021066144A1 (ja) 2021-12-02
EP4043014A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
JP7248836B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
JP2022116191A (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
US20200338094A1 (en) Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
Gonzalez-Salinas et al. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: a randomized, controlled, double-masked clinical trial
HRP20030202A2 (en) A method of analgesia
WO2021213484A1 (zh) 秦艽及其单体化合物在杀螨中的应用
TWI617306B (zh) 醫藥組成物及其用途
Dux et al. High‐dose phenylephrine increases meningeal blood flow through TRPV1 receptor activation and release of calcitonin gene‐related peptide
CA3101878A1 (en) Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
HK1225971A1 (zh) 使用拉喹莫德治疗青光眼
WO2022123837A1 (ja) 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法
CN110013498A (zh) 一种含盐酸奥洛他定的滴眼液及其制备方法
US12502375B2 (en) Pharmaceutical drug containing heterocyclidene acetamide derivative
US20210379078A1 (en) Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor
TW200918075A (en) Compositions and methods for modulating endophthalmitis using fluoroquinolones
WO2019060994A1 (en) COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF LOWE SYNDROME OR TOOTH DISEASE, AND METHODS THEREOF
Chen et al. Vitamin K1 Alleviates Retinal Inflammation Following Acute Ocular Hypertension by Modulating Microglial Ferroptosis
US20220071924A1 (en) Treatment of ocular diseases with ophthalmic tapinarof compositions
BR122025000958A2 (pt) Composições contendo derivado de heterociclideno acetamida e seus usos
JP2017518333A (ja) 神経系の変性疾患を治療及び予防するためのｐ３８及びｊｎｋ ｍａｐｋ阻害剤
KR102902220B1 (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
JP6206782B2 (ja) 人工涙液の組成物
Xiang et al. Exercise-Induced Irisin Attenuates Trabecular Meshwork Fibrosis and Calcification Via Integrin Αvβ5 Signaling in Glaucoma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000